AtriCure (ATRC)
(Delayed Data from NSDQ)
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -6.67% and 6.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 2.07% and 1.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Q4 Earnings Lag Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OrganiGram (OGI) Surges: Stock Moves 8.9% Higher
by Zacks Equity Research
OrganiGram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 67.65% and 13.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 64.29% and 16.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure Enters Overbought Territory
by Zacks Equity Research
AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.